TA1011 · single_technology_appraisal
Cancer Drugs Fund data collection arrangement for the single technology appraisal of belzutifan for treating tumours associated with von Hippel-Lindau disease
Recommended for Cancer Drugs FundAugust 2024
Managed Access Agreement with Cancer Drugs Fund - data collection arrangement. Treatment to be continued until disease progression, unacceptable toxicity, patient choice to stop, or occurrence of intervention with localised procedure. Monotherapy only for VHL-associated RCC, CNS haemangioblastoma, and/or pNET where localised procedures are unsuitable or undesirable.
Intervention
belzutifan (Not stated) · HIF-2α inhibitor · Not stated
Conditions
tumours associated with von hippel-lindau diseaseoncology · locally_advanced
von hippel-lindau disease-associated tumoursoncology · metastatic
Clinical trials
| Trial | Design | Phase | Pivotal |
|---|
| LITESPARK-004 | single_arm | Phase II | — |
Evidence gaps
short follow up—Long-term efficacy of belzutifan
single arm evidence only—LITESPARK-004 is a single-arm trial with no comparator
immature overall survival—Treatment waning and long-term safety profile
Commercial arrangement
managed access agreement · critical for recommendation
Special considerations
Cancer Drugs Fund eligible